LAG3 and neoplasm: While both β3-AR antagonism and αPD-L1 treatment, or their combination, did not significantly affect the number of PD1+CD4+, TIM3+CD4+, and LAG-3+CD4+ cells (Fig. 3A–C), neither the number of TIM3+CD8+ and LAG-3+CD8+ cells (Fig. 3E, F), they did significantly increase the number of PD1+CD8+ T cells (Fig. 3D) compared to vehicle in tumor mass of NB-bearing mice after ten days of treatment.